Lei Q, Huang Y, Deng F, Zheng H, Hong X, Wang P
Discov Oncol. 2025; 16(1):69.
PMID: 39836310
PMC: 11751243.
DOI: 10.1007/s12672-024-01551-7.
Gutierrez-Chakraborty E, Chakraborty D, Das D, Bai Y
Expert Syst Appl. 2025; 252(Pt B.
PMID: 39829683
PMC: 11737334.
DOI: 10.1016/j.eswa.2024.124239.
Jiang Y, Chen J, Xu L, Lv L, Gan X
J Cancer. 2025; 16(3):917-931.
PMID: 39781352
PMC: 11705051.
DOI: 10.7150/jca.100724.
Cheng Q, Han X, Xie H, Liao Y, Wang F, Cui X
Biomed Rep. 2025; 22(3):38.
PMID: 39781045
PMC: 11704871.
DOI: 10.3892/br.2024.1916.
Li S, Lin Y, Gao X, Zeng D, Cen W, Su Y
Front Immunol. 2024; 15:1517312.
PMID: 39712016
PMC: 11659151.
DOI: 10.3389/fimmu.2024.1517312.
Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females.
Gan X, Zhou Y, Li Y, Xu L, Liu G
Discov Oncol. 2024; 15(1):812.
PMID: 39699604
PMC: 11659565.
DOI: 10.1007/s12672-024-01636-3.
Prognostic, oncogenic roles, and pharmacogenomic features of AMD1 in hepatocellular carcinoma.
Zhou Y, Zhou Y, Hu J, Xiao Y, Zhou Y, Yu L
Cancer Cell Int. 2024; 24(1):398.
PMID: 39695661
PMC: 11654270.
DOI: 10.1186/s12935-024-03593-x.
Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma.
Teo J, Chen Z, Chen W, Tan R, Cao Q, Chu Y
J Exp Med. 2024; 222(1).
PMID: 39636298
PMC: 11619716.
DOI: 10.1084/jem.20241442.
ATP6V1C1, associated with the tumor microenvironment and mTORC1 signaling pathway, is a potential diagnostic, prognostic, and therapeutic biomarker for hepatocellular carcinoma.
Pan Y, Chen H, Lv C, He W, Xu Y, Xuan Q
Discov Oncol. 2024; 15(1):673.
PMID: 39557733
PMC: 11573946.
DOI: 10.1007/s12672-024-01578-w.
Single-cell and spatial transcriptomics reveal apelin/APJ pathway's role in microvessel formation and tumour progression in hepatocellular carcinoma.
Zhu Y, Zhang P, Huo X, Ling Y, Lv X, Lin S
J Cell Mol Med. 2024; 28(20):e70152.
PMID: 39434201
PMC: 11493554.
DOI: 10.1111/jcmm.70152.
TRPM8 overexpression suppresses hepatocellular carcinoma progression and improves survival by modulating the RTP3/STAT3 pathway.
Chen L, Xu N, Gou D, Song J, Zhou M, Zhang Y
Cancer Med. 2024; 13(19):e70109.
PMID: 39385506
PMC: 11464657.
DOI: 10.1002/cam4.70109.
Spatial single-cell protein landscape reveals vimentin macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma.
Qiu X, Zhou T, Li S, Wu J, Tang J, Ma G
Nat Cancer. 2024; 5(10):1557-1578.
PMID: 39327501
DOI: 10.1038/s43018-024-00824-y.
MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.
Lu X, Zhang Y, Xue J, Evert M, Calvisi D, Chen X
Toxicol Sci. 2024; 203(1):41-51.
PMID: 39316419
PMC: 11664104.
DOI: 10.1093/toxsci/kfae126.
Unveiling Disparities: Analyzing Hispanic Inclusion in Liver Cancer Research Databases in the United States.
Figueroa G, Greten T, Bonilla C
J Racial Ethn Health Disparities. 2024; .
PMID: 39312090
DOI: 10.1007/s40615-024-02178-8.
NFKBIE is a predictive factor of survival and is correlated with immune infiltration and antigen processing and presentation in hepatocellular carcinoma.
Zhang Y, Tu J, Wang J, Dai T, Zheng L, Sun S
Oncol Lett. 2024; 28(4):480.
PMID: 39161335
PMC: 11332585.
DOI: 10.3892/ol.2024.14613.
Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma.
Zhai S, Li Y, Yang Y, Lang W, Liu X, Liu K
Front Immunol. 2024; 15:1361657.
PMID: 39108273
PMC: 11300247.
DOI: 10.3389/fimmu.2024.1361657.
Identification of SLC7A11-AS1/SLC7A11 pair as a ferroptosis-related therapeutic target for hepatocellular carcinoma.
Yuan X, Wang Y, Jiao S, Gao H, Zhang M, Wang X
J Cell Mol Med. 2024; 28(13):e18496.
PMID: 38984939
PMC: 11234646.
DOI: 10.1111/jcmm.18496.
Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma.
Cao L, Li F, Cai S, Zhang J, Guo C, Ali S
Sci Rep. 2024; 14(1):15870.
PMID: 38982153
PMC: 11233571.
DOI: 10.1038/s41598-024-66838-9.
PWP1 is overexpressed in hepatocellular carcinoma and facilitates liver cancer cell proliferation.
Huang R, Xu F, Su L, Lu Y, Liu W, Liu S
Heliyon. 2024; 10(11):e32409.
PMID: 38933950
PMC: 11200354.
DOI: 10.1016/j.heliyon.2024.e32409.
Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
Li Q, Guo W, Qian Y, Li S, Li L, Zhu Z
J Immunother Cancer. 2024; 12(6).
PMID: 38908854
PMC: 11328658.
DOI: 10.1136/jitc-2024-008917.